Antonio Gonzalez, MD
General Practice · Immokalee, FLNPI 1720047152
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,887 of the $4,549 with a category attached, or 63.5%. 16 manufacturers reported payments, led by Merck at 32.6% of the total. Reporting peaked in 2023 at $1,721 and has fallen 92.8% since, to $124 in 2025. Among general practice clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $38.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- AstraZeneca$828
- Boehringer Ingelheim$811
- Intuitive Surgical$447
- Novo Nordisk$298
- Amgen$196
- plus $485 from 10 others
Across 89 payments — averaging $19,923 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.4M
- GSK$225K
- Pfizer$45K
- Sekisui Diagnostics LLC$32K
- BD$32K
- AstraZeneca$23K
What the payments were for
- Travel & lodging$1,63436%
- Food & beverage$2,88763%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $1,483 |
| AstraZeneca(2 entities) | 28 | $828 |
| Boehringer Ingelheim | 36 | $811 |
| Intuitive Surgical | 3 | $447 |
| Novo Nordisk | 14 | $298 |
| Amgen(2 entities) | 6 | $196 |
| Redhill Biopharma Inc. | 8 | $129 |
| Lilly USA, LLC | 4 | $127 |
| Johnson & Johnson | 1 | $109 |
| Mannkind Corporation | 1 | $22 |
| Novartis | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Pfizer | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Abbott | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,549 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 80 | $98,492 |
| JardianceEmpagliflozin | 27 | $34,240 |
| JanuviaSitagliptin Phosphate | 13 | $20,788 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $12,770 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,946 |
| Omega-3 Acid Ethyl Esters | 30 | $4,952 |
| Alcohol PadsAlcohol Antiseptic Pads | 35 | $4,849 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $3,493 |
| Megestrol Acetate | 15 | $3,456 |
| Sulindac | 230 | $3,110 |
| Comfort Ez Pro Safety Pen NdlPen Needle, Diabetic, Safety | 13 | $3,021 |
| Diclofenac Sodium | 85 | $2,681 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 20 | $2,436 |
| Easy Comfort Alcohol PadAlcohol Antiseptic Pads | 25 | $2,220 |
| Omeprazole | 67 | $1,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $828 | $98,49280 claims |
| Boehringer IngelheimJardiance | $811 | $34,24027 claims |
| MerckJanuvia, Janumet Xr | $1,483 | $33,55726 claims |
| Lilly USA, LLCHumulin 70-30 | $127 | $2,43620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Immokalee
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
- Sarah JockinTampa$308K
- Mario RomeroSarasota$275K
- Robert RitterJupiter$233K
- Robert AltharPensacola$231K
- Florencia ZiemkeWest Palm Beach$208K
- Ausberto HidalgoPembroke Pines$171K
- Rickie FergusonPembroke Pines$170K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.